{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:33:10Z","timestamp":1712536390842},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,7]]},"DOI":"10.7759\/cureus.57777","type":"journal-article","created":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T22:33:06Z","timestamp":1712529186000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical Efficacy and Safety of Low-Dose Pemafibrate in Patients With Severe Renal Impairment: A Retrospective Study"],"prefix":"10.7759","author":[{"given":"Hisato","family":"Shima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Tashiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyoshi","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiichiro","family":"Wariishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Doi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Minakuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options","volume":"143","author":"Jankowski J","year":"2021","unstructured":"Jankowski J, Floege J, Fliser D, B\u00f6hm M, Marx N. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation. 2021, 143:1157-72. 10.1161\/CIRCULATIONAHA.120.050686","journal-title":"Circulation"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-013-0866-9","article-title":"Lipoprotein metabolism and CKD: overview","volume":"18","author":"Barter P","year":"2014","unstructured":"Barter P. Lipoprotein metabolism and CKD: overview. Clin Exp Nephrol. 2014, 18:243-6. 10.1007\/s10157-013-0866-9","journal-title":"Clin Exp Nephrol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard BG","year":"2014","unstructured":"Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014, 384:626-35. 10.1016\/S0140-6736(14)61177-6","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2014.08.028","article-title":"Fasting and non-fasting triglycerides and risk of ischemic cardiovascular disease in Japanese men and women: the Circulatory Risk in Communities Study (CIRCS)","volume":"237","author":"Iso H","year":"2014","unstructured":"Iso H, Imano H, Yamagishi K, et al.. Fasting and non-fasting triglycerides and risk of ischemic cardiovascular disease in Japanese men and women: the Circulatory Risk in Communities Study (CIRCS). Atherosclerosis. 2014, 237:361-8. 10.1016\/j.atherosclerosis.2014.08.028","journal-title":"Atherosclerosis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1246","article-title":"Plasma triglycerides and HDL-C levels predict the development of diabetic kidney disease in subjects with type 2 diabetes: the AMD Annals Initiative","volume":"39","author":"Russo GT","year":"2016","unstructured":"Russo GT, De Cosmo S, Viazzi F, et al.. Plasma triglycerides and HDL-C levels predict the development of diabetic kidney disease in subjects with type 2 diabetes: the AMD Annals Initiative. Diabetes Care. 2016, 39:2278-87. 10.2337\/dc16-1246","journal-title":"Diabetes Care"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20030706","article-title":"Long-term efficacy and safety of Pemafibrate, a novel selective peroxisome proliferator-activated receptor-\u03b1 modulator (SPPARM\u03b1), in dyslipidemic patients with renal impairment","volume":"20","author":"Yokote K","year":"2019","unstructured":"Yokote K, Yamashita S, Arai H, Araki E, Suganami H, Ishibashi S on Behalf of the K-877 Study Group. Long-term efficacy and safety of Pemafibrate, a novel selective peroxisome proliferator-activated receptor-\u03b1 modulator (SPPARM\u03b1), in dyslipidemic patients with renal impairment. Int J Mol Sci. 2019, 20:706. 10.3390\/ijms20030706","journal-title":"Int J Mol Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.07.049","article-title":"Effects of fibrates in kidney disease: a systematic review and meta-analysis","volume":"60","author":"Jun M","year":"2012","unstructured":"Jun M, Zhu B, Tonelli M, et al.. Effects of fibrates in kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol. 2012, 60:2061-71. 10.1016\/j.jacc.2012.07.049","journal-title":"J Am Coll Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-12-82","article-title":"Selective peroxisome proliferator-activated receptor \u03b1 modulators (SPPARM\u03b1): the next generation of peroxisome proliferator-activated receptor \u03b1-agonists","volume":"12","author":"Fruchart JC","year":"2013","unstructured":"Fruchart JC. Selective peroxisome proliferator-activated receptor \u03b1 modulators (SPPARM\u03b1): the next generation of peroxisome proliferator-activated receptor \u03b1-agonists. Cardiovasc Diabetol. 2013, 12:82. 10.1186\/1475-2840-12-82","journal-title":"Cardiovasc Diabetol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-020-0823-5","article-title":"Pemafibrate, a new selective PPAR\u03b1 modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases","volume":"22","author":"Yamashita S","year":"2020","unstructured":"Yamashita S, Masuda D, Matsuzawa Y. Pemafibrate, a new selective PPAR\u03b1 modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases. Curr Atheroscler Rep. 2020, 22:5. 10.1007\/s11883-020-0823-5","journal-title":"Curr Atheroscler Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr3949","article-title":"Half dose once-daily Pemafibrate effectively improved hypertriglyceridemia in real practice","volume":"11","author":"Iitake C","year":"2019","unstructured":"Iitake C, Iitake K. Half dose once-daily Pemafibrate effectively improved hypertriglyceridemia in real practice. J Clin Med Res. 2019, 11:690-5. 10.14740\/jocmr3949","journal-title":"J Clin Med Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.31662\/jmaj.2020-0104","article-title":"Efficacy and safety of low-dose Pemafibrate therapy for hypertriglyceridemia in patients with type 2 diabetes","volume":"4","author":"Bando H","year":"2021","unstructured":"Bando H, Taneda S, Manda N. Efficacy and safety of low-dose Pemafibrate therapy for hypertriglyceridemia in patients with type 2 diabetes. JMA J. 2021, 4:135-40. 10.31662\/jmaj.2020-0104","journal-title":"JMA J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2009.151","article-title":"Myopathy with statin-fibrate combination therapy: clinical considerations","volume":"5","author":"Jacobson TA","year":"2009","unstructured":"Jacobson TA. Myopathy with statin-fibrate combination therapy: clinical considerations. Nat Rev Endocrinol. 2009, 5:507-18. 10.1038\/nrendo.2009.151","journal-title":"Nat Rev Endocrinol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/srep42477","article-title":"Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis","volume":"7","author":"Honda Y","year":"2017","unstructured":"Honda Y, Kessoku T, Ogawa Y, et al.. Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis. Sci Rep. 2017, 7:42477. 10.1038\/srep42477","journal-title":"Sci Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.6871-20","article-title":"Real-world profile of a selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1) in Japanese patients with renal impairment and dyslipidemia","volume":"60","author":"Komatsu T","year":"2021","unstructured":"Komatsu T, Miura T, Joko K, Sunohara D, Mochidome T, Kasai T, Ikeda U. Real-world profile of a selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1) in Japanese patients with renal impairment and dyslipidemia. Intern Med. 2021, 60:2741-8. 10.2169\/internalmedicine.6871-20","journal-title":"Intern Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.01.013","article-title":"NAFLD as a driver of chronic kidney disease","volume":"72","author":"Byrne CD","year":"2020","unstructured":"Byrne CD, Targher G. NAFLD as a driver of chronic kidney disease. J Hepatol. 2020, 72:785-801. 10.1016\/j.jhep.2020.01.013","journal-title":"J Hepatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1073025","article-title":"Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients","volume":"10","author":"Sugimoto R","year":"2023","unstructured":"Sugimoto R, Iwasa M, Eguchi A, et al.. Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients. Front Med (Lausanne). 2023, 10:1073025. 10.3389\/fmed.2023.1073025","journal-title":"Front Med (Lausanne)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10020401","article-title":"Effects of a novel selective peroxisome proliferator-activated receptor \u03b1 modulator, Pemafibrate, on metabolic parameters: a retrospective longitudinal study","volume":"10","author":"Yanai H","year":"2022","unstructured":"Yanai H, Katsuyama H, Hakoshima M. Effects of a novel selective peroxisome proliferator-activated receptor \u03b1 modulator, Pemafibrate, on metabolic parameters: a retrospective longitudinal study. Biomedicines. 2022, 10:401. 10.3390\/biomedicines10020401","journal-title":"Biomedicines"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/244422-clinical-efficacy-and-safety-of-low-dose-pemafibrate-in-patients-with-severe-renal-impairment-a-retrospective-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T22:33:10Z","timestamp":1712529190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/244422-clinical-efficacy-and-safety-of-low-dose-pemafibrate-in-patients-with-severe-renal-impairment-a-retrospective-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,7]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.57777","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,7]]}}}